Abstract 125P
Background
Bevacizumab biosimilar (Avegra®) became available for patients in Russia since 2015. Since introduction, no real-world data except clinical cases was available. We decided to assess the safety and effectiveness of Avegra® in patients treated in daily practice according to national treatment protocols. Depending on the geography the study was divided into Apollon-11, conducted in Moscow, and Soyuz-Apollon, conducted in 18 regions of Russia. The final analysis summarizes pooled results of all regions.
Methods
This multicentre prospective observational post-authorization study of bevacizumab biosimilar combined with chemotherapy in patients with metastatic colorectal cancer was conducted in 28 centres in Russia from December 2019 to January 2023. Patients with metastatic colorectal cancer (mCRC), treated with bevacizumab at a dose of 5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks in combination with standard chemotherapy regimens as a first line of therapy were included. Primary safety endpoints were the incidence of adverse reactions (ARs) related to bevacizumab and the rate of treatment discontinuation due to ARs.
Results
438 patients with mCRC in 28 research centres of the Russian Federation were included in the study. Median age of patients was 62 (28–87) years, ECOG performance status of £1. Most of the tumors were left-sided (67.8%) and had at least one RAS/BRAF mutation (55.9%). After median follow-up of 7.3 months, adverse reactions occurred in 11%, of which 2.7% were grade ³3. Treatment was discontinued in 2.8% of patients due to adverse reactions. Objective response was achieved in 37.9% of patients (95% CI 31.4 - 41.6) with 2.8% of complete responses. Median progression-free survival was 9.4 months (95% CI 8.1 - 10.7). Median overall survival was not reached.
Conclusions
Our findings are consistent with previously known bevacizumab safety and efficacy profile. Numerically low incidence of ARs is most likely due to reduced reporting of adverse events in real-world clinical practice settings.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
BIOCAD.
Funding
BIOCAD.
Disclosure
A. Tryakin, M. Fedyanin, F.V. Moiseenko: Financial Interests, Personal, Coordinating PI: BIOCAD. M. Mariam, O. Mironov, D. Stroyakovskiy, N. Sokolov, S. Orlova, E. Mantsyrev, A.V. Sultanbaev, A. Teterich, K. Babina, D. Yukalchuk, S. Borzyanitsa, A. Isyangulova, A. Saidullaeva, I. Chernova, E. Bobrova, N. Fadeeva: Financial Interests, Personal, Local PI: BIOCAD.
Resources from the same session
122P - Distinct transcriptomic immune profiling and clinicopathological features of cribriform morphology in colorectal adenocarcinomas
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract
123P - Spatial molecular profiling identifies FGF20 upregulation on cancer-associated fibroblast and FGFR2-PI3K/Akt activation in tumor cells of sporadic early-onset colon cancer
Presenter: Dave Hoon
Session: Poster Display
Resources:
Abstract
124P - Characteristics, prognosis and therapeutic effects of non-V600 BRAF mutated colorectal cancer
Presenter: Lalida Arsa
Session: Poster Display
Resources:
Abstract
126P - From tumor height (TH) to tumor regression grade (TRG) in locally advanced rectal cancers (LARC) during total neadjuvant therapy (TNT): A retrospective analysis
Presenter: Valeria Pusceddu
Session: Poster Display
Resources:
Abstract
127P - A meta-analysis of efficacy and safety from head-to-head first-line (1L) trials of epidermal growth factor receptor inhibitors (EGFRIs) versus bevacizumab in combination with chemotherapy (CT) doublets in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) by sidedness
Presenter: Takayuki Yoshino
Session: Poster Display
Resources:
Abstract
128TiP - A phase II study of cadonilimab + FOLFOXIRI and bevacizumab as initial therapy for unresectable proficient mismatch repair/microsatellite stable (pMMR/MSS) metastatic colorectal cancer (mCRC)
Presenter: Rongbo Lin
Session: Poster Display
Resources:
Abstract
140P - Prevalence of claudin-18 isoform 2 (CLDN18.2) positivity in locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mg/GEJ) adenocarcinoma in patients (pts) in the Asia region: Phase III SPOTLIGHT and GLOW studies
Presenter: Hoo Hwoei Fen Soo
Session: Poster Display
Resources:
Abstract
141P - Early phase trials outcomes in refractory upper GI cancers: A 10-year analysis from the SCRI UK phase I unit
Presenter: Antonella Cammarota
Session: Poster Display
Resources:
Abstract
142P - The survival impact of the addition of durvalumab to cisplatin/gemcitabine in advanced biliary tract cancer: A real-world, retrospective, multicentric study
Presenter: Silvia Foti
Session: Poster Display
Resources:
Abstract
143P - Ablation combined with tislelizumab in treating hepatocellular carcinoma: A phase II trial
Presenter: Yangxun Pan
Session: Poster Display
Resources:
Abstract